Page last updated: 2024-11-12
isomalyngamide a
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
isomalyngamide A: from the Hawaiian cyanobacterium Lyngbya majuscula; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 10626553 |
| CHEMBL ID | 2147270 |
| MeSH ID | M0379932 |
Synonyms (4)
| Synonym |
|---|
| isomalyngamide a |
| CHEMBL2147270 |
| (e,7s)-n-[(e,2z)-2-(chloromethylidene)-4-methoxy-6-(3-methoxy-5-oxo-2h-pyrrol-1-yl)-6-oxohex-4-enyl]-7-methoxy-n-methyltetradec-4-enamide |
| DTXSID901046525 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Bioassays (6)
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID687959 | Antimetastatic activity in human MDA-MB-231 cells assessed as inhibition of serum-induced cellular migration at 150 nM after 24 hrs by wound healing assay | 2011 | European journal of medicinal chemistry, Sep, Volume: 46, Issue:9 | Isomalyngamide A, A-1 and their analogs suppress cancer cell migration in vitro. |
| AID687960 | Antimetastatic activity in human MDA-MB-231 cells assessed as inhibition of cell migration-associated wound closure at 150 nM after 24 hrs of scratching by wound-healing assay | 2011 | European journal of medicinal chemistry, Sep, Volume: 46, Issue:9 | Isomalyngamide A, A-1 and their analogs suppress cancer cell migration in vitro. |
| AID687958 | Antimetastatic activity in human MDA-MB-231 cells assessed as inhibition of serum-induced cellular migration after 16 hrs by Boyden chamber assay | 2011 | European journal of medicinal chemistry, Sep, Volume: 46, Issue:9 | Isomalyngamide A, A-1 and their analogs suppress cancer cell migration in vitro. |
| AID687954 | Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay | 2011 | European journal of medicinal chemistry, Sep, Volume: 46, Issue:9 | Isomalyngamide A, A-1 and their analogs suppress cancer cell migration in vitro. |
| AID687956 | Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by MTT assay | 2011 | European journal of medicinal chemistry, Sep, Volume: 46, Issue:9 | Isomalyngamide A, A-1 and their analogs suppress cancer cell migration in vitro. |
| AID687968 | Inhibition of rat liver alpha 2,3-sialyltransferase | 2011 | European journal of medicinal chemistry, Sep, Volume: 46, Issue:9 | Isomalyngamide A, A-1 and their analogs suppress cancer cell migration in vitro. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
Research
Studies (6)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (16.67) | 29.6817 |
| 2010's | 4 (66.67) | 24.3611 |
| 2020's | 1 (16.67) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 12.38
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.38) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 6 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||